InsiderTrades.com logo
Banking failure dead ahead
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Henry J. Fuchs net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Henry Fuchs Biography and Net Worth

Director of Mirati Therapeutics
Henry J. Fuchs, M.D., joined BioMarin in March 2009 and currently serves as our President of Worldwide Research & Development. From December 2009 to October 2016, Dr. Fuchs served as our Executive Vice President and Chief Medical Officer. From March 2009 to December 2009, Dr. Fuchs served as our Senior Vice President and Chief Medical Officer. From September 2005 until December 2008, Dr. Fuchs served as Executive Vice President and Chief Medical Officer for Onyx Pharmaceuticals, a biopharmaceutical company. Dr. Fuchs served as Chief Executive Officer of Ardea Biosciences, Inc. from January 2003 until June 2005. Dr. Fuchs first joined Ardea Biosciences, Inc. as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996, Dr. Fuchs held various positions at Genentech, Inc. where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme, a therapeutic for cystic fibrosis. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University. Dr. Fuchs is currently a director of Mirati Therapeutics, a public biopharmaceutical company. He was on the board of Ardea Biosciences, Inc. from 1996 until its acquisition by AstraZeneca PLC in 2012, and he was also on the board of Genomic Health, Inc. from 2013 until its acquisition by Exact Sciences in 2019.

What is Henry J. Fuchs' net worth?

The estimated net worth of Henry J. Fuchs is at least $12.45 million as of March 5th, 2024. Dr. Fuchs owns 212,117 shares of Mirati Therapeutics stock worth more than $12,451,268 as of November 7th. This net worth approximation does not reflect any other assets that Dr. Fuchs may own. Learn More about Henry J. Fuchs' net worth.

How do I contact Henry J. Fuchs?

The corporate mailing address for Dr. Fuchs and other Mirati Therapeutics executives is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. Mirati Therapeutics can also be reached via phone at (858) 332-3410 and via email at [email protected]. Learn More on Henry J. Fuchs' contact information.

Has Henry J. Fuchs been buying or selling shares of Mirati Therapeutics?

Henry J. Fuchs has not been actively trading shares of Mirati Therapeutics during the last quarter. Most recently, Henry J. Fuchs sold 10,000 shares of the business's stock in a transaction on Tuesday, December 15th. The shares were sold at an average price of $233.39, for a transaction totalling $2,333,900.00. Learn More on Henry J. Fuchs' trading history.

Who are Mirati Therapeutics' active insiders?

Mirati Therapeutics' insider roster includes Charles Baum (CEO), Bruce Carter (Director), Julie Cherrington (Director), Jamie Christensen (EVP), Daniel Faga (COO), Henry Fuchs (Director), Benjamin Hickey (EVP), Craig Johnson (Director), and Vickie Reed (CAO). Learn More on Mirati Therapeutics' active insiders.

Are insiders buying or selling shares of Mirati Therapeutics?

In the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 7,438 shares worth more than $433,243.25. The most recent insider tranaction occured on January, 16th when EVP Benjamin Hickey sold 1,597 shares worth more than $94,254.94. Insiders at Mirati Therapeutics own 3.3% of the company. Learn More about insider trades at Mirati Therapeutics.

Information on this page was last updated on 1/16/2024.

Henry J. Fuchs Insider Trading History at Mirati Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2020Sell10,000$233.39$2,333,900.00
8/10/2020Sell10,000$131.38$1,313,800.0012,000View SEC Filing Icon  
See Full Table

Henry J. Fuchs Buying and Selling Activity at Mirati Therapeutics

This chart shows Henry J Fuchs's buying and selling at Mirati Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mirati Therapeutics Company Overview

Mirati Therapeutics logo
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $58.70
Low: $58.70
High: $58.70

50 Day Range

MA: $58.82
Low: $58.70
High: $59.28

2 Week Range

Now: $58.70
Low: $27.30
High: $64.41

Volume

N/A

Average Volume

2,758,857 shs

Market Capitalization

$4.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77
War on Elon Escalates…
From Porter & Company   |   Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.